Clearpoint Neuro Inc
$ 13.39
1.75%
06 Aug - close price
- Market Cap 408,452,000 USD
- Current Price $ 13.39
- High / Low $ 13.46 / 12.94
- Stock P/E N/A
- Book Value 0.35
- EPS -1.00
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -2.27 %
- 52 Week High 30.10
- 52 Week Low 8.27
About
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Analyst Target Price
$25.67
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-13 | 2026-03-17 | 2025-11-06 | 2025-08-12 | 2025-05-13 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-03-12 | 2023-11-09 |
| Reported EPS | -0.38 | -0.32 | -0.27 | -0.21 | -0.21 | -0.22 | -0.2 | -0.18 | -0.16 | -0.16 | -0.19 | -0.2 |
| Estimated EPS | -0.29 | -0.27 | -0.185 | -0.2 | -0.2 | -0.16 | -0.1737 | -0.17 | -0.18 | -0.19 | -0.2 | -0.25 |
| Surprise | -0.09 | -0.05 | -0.085 | -0.01 | -0.01 | -0.06 | -0.0263 | -0.01 | 0.02 | 0.03 | 0.01 | 0.05 |
| Surprise Percentage | -31.0345% | -18.5185% | -45.9459% | -5% | -5% | -37.5% | -15.141% | -5.8824% | 11.1111% | 15.7895% | 5% | 20% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLPT
2026-08-06 11:11:18
ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently released its latest quarterly results, leading analysts to significantly reduce their earnings forecasts for the company. Despite the downward revisions, the consensus price target remains largely unchanged at US$17.17, suggesting that analysts still see potential for share price appreciation. The article delves into the updated analyst ratings and the potential implications for investors.
2026-08-06 11:11:18
ClearPoint Neuro, Inc. (NASDAQ:CLPT) recently missed its second-quarter earnings expectations, with revenues 15% below forecasts and statutory losses increasing significantly. This has led analysts to downgrade revenue estimates for 2026 and project higher per-share losses, resulting in a 9.4% reduction in the consensus price target. Despite the lowered outlook, analysts still expect ClearPoint Neuro to grow faster than the broader industry.
2026-08-04 20:14:40
An amended Schedule 13G filing reveals that investors led by Bigger Capital Fund, LP have disclosed a beneficial ownership stake of 7.45% in ClearPoint Neuro (CLPT). Michael Bigger, through various affiliations and personal holdings, is deemed to beneficially own 2,272,980 shares of the common stock. This filing details the ownership percentages of several entities and individuals, based on 30,504,227 shares outstanding as of July 27, 2026.
2026-08-04 14:42:02
Stifel lowered its price target for Clearpoint Neuro (NASDAQ:CLPT) from $25 to $22, while maintaining a Buy rating, following the company's guidance cut. Clearpoint Neuro reported second-quarter revenue of $10.9 million, missing estimates, and reduced its 2026 revenue guidance by 7% to $50 million. This strategic shift reflects an increased focus on building clinical capacity and expanding into focused ultrasound.
2026-08-04 10:14:40
Clearpoint Neuro Inc. has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv, gives an overview of the company's financial performance during this period.
2026-08-04 10:14:40
ClearPoint Neuro (CLPT) reported Q2 2026 revenue of $10.88 million, an 18% increase year-over-year, but missed the Zacks Consensus Estimate of $13 million. The company posted an EPS of -$0.38, also missing the consensus estimate of -$0.29. Key metric analysis revealed varied performance across its business segments, with Neurosurgery navigation and therapy revenue up 64.7% but Biologics and drug delivery revenue down 14.9%.
